T2372 |
PonatinibHOT |
Ponatinib is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).
|
|
T6230 |
ImatinibHOT |
matinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit (IC50: 600/100/100 nM).
|
|
T1621 |
Imatinib MesylateHOT |
Imatinib mesylate is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectiv...
|
|
T1524 |
NilotinibHOT |
Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
|
|
T1448 |
DasatinibHOT |
Dasatinib is a potent inhibitor of the Bcr-Abl and Src family (IC50s: 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit, and c-KitD816V, respectively).
|
|
T0152 |
BosutinibHOT |
Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
|
|
T21785 |
AG957 |
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in ch...
|
|
T2116 |
AEE788 |
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
|
T6300 |
Degrasyn |
Degrasyn (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without a...
|
|
T3196 |
GNF-7 |
GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.
|
|
T2094 |
Danusertib |
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
|
|
T2609 |
Masitinib |
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has ...
|
|
T1803 |
GNF-5 |
GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properti...
|
|
T1817 |
GNF-2 |
GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.
|
|
T1754 |
ZM 306416 |
ZM 306416, a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).
|
|
T2920 |
Berbamine dihydrochloride |
Berbamine dihydrochloride, a natural compound derived from the Berberis amurensis plant, has been shown to exhibit antitumor activity in several Ys.
|
|
T2802 |
Nocodazole |
Nocodazole is a synthetic inhibitor of microtubule polymerization, also inhibits Abl (IC50: 0.21 μM), Abl(E255K, IC50: 0.53 μM) and Abl(T315I, IC50: 0.64 μM) ...
|
|
T6128 |
PHA-665752 |
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
|
|
T3641 |
NVP-BAW2881 |
BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and ac...
|
|
T3063 |
PD173955 |
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PK...
|
|
T6196 |
PP1 |
PP1, a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
|
|
T2429 |
Olverembatinib dimesylate |
GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
|
|
T3071 |
Olverembatinib |
GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
|
|
T6057 |
URMC-099 |
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|
|
T6650 |
Sabutoclax |
Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
|
|
T2070 |
Agerafenib |
CEP-32496 is a highly potent inhibitor of BRAF.
|
|
T2415 |
PP121 |
PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , ...
|
|
T2293 |
SGX-523 |
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
|
|
T6311 |
Bafetinib |
Bafetinib (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I mutant and ...
|
|
T3068 |
AT9283 |
AT9283 is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
|
|
T1448L |
Dasatinib monohydrate |
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoti...
|
|
T10799 |
CHMFL-ABL-039 |
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloi...
|
|
T8882 |
Vodobatinib |
Vodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
|
|
T2341 |
KW-2449 |
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1...
|
|
T2147 |
Nilotinib monohydrochloride monohydrate |
Nilotinib monohydrochloride monohydrate is significantly potent BCR-ABL against, is a second generation tyrosine kinase inhibitor (TKI), and is active against ma...
|
|
T22553 |
Adaphostin |
Adaphostin is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.
|
|
T22378 |
Nilotinib hydrochloride |
Nilotinib hydrochloride, the hydrochloride salt form of nilotinib, is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
|
|
T22303 |
Dasatinib hydrochloride |
Dasatinib hydrochloride is a highly ATP competitive, potent, orally active inhibitor of dual Src/Bcr-Abl(with Ki values of 16 pM and 30 pM for Src and Bcr-Abl, r...
|
|
T17267 |
XL228 |
XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).
|
|
T11916 |
Lyn-IN-1 |
Lyn-IN-1 is a selective and potent dual inhibitor of Bcr-Abl and Lyn
|
|
T16750 |
Rigosertib |
Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which...
|
|
T16545 |
Pivanex |
Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
|
|
T8488 |
GMB-475 |
GMB-475 is a BCR-ABL1 tyrosine kinase degrader based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the ...
|
|
T10800 |
CHMFL-ABL-121 |
CHMFL-ABL-121 is a highly potent inhibitor of type II ABL kinase (IC50s: 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein).
|
|
T11641 |
N-Desmethyl imatinib |
N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
|
|
T25476 |
Gypsogenin |
Gypsogenin is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.
|
|
T10583 |
Bosutinib D8 |
Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
|
|
T10488 |
BCR-ABL-IN-1 |
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
|
|
T12907 |
SIAIS178 |
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
|
|
T14925 |
Cenisertib |
Cenisertib (AS-703569) is a multi-kinase inhibitor and blocks the activity of Aurora-kinase-A/B, AKT, ABL1, STAT5, and FLT3. Cenisertib inhibits tumor growth in ...
|
|
T7861 |
Flumatinib mesylate |
Flumatinib mesylate is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
|
|
T7186 |
CZC-8004 |
CZC-8004 is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.
|
|
T5177 |
Asciminib |
Asciminib (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).
|
|
T4618 |
BGG463 |
BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
|
|
T4320 |
Flumatinib |
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
|
|
T6348 |
NVP-BHG712 |
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
|
|
T2328 |
Radotinib |
Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosom...
|
|
T6314 |
(R)-(-)-Gossypol |
AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM.
|
|
T2640 |
Rebastinib |
DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT...
|
|